Dr. Reddy's Laboratories Limited Logo

Dr. Reddy's Laboratories Limited

RDY

(4.0)
Stock Price

14,20 USD

14.86% ROA

20.28% ROE

19.84x PER

Market Cap.

1.101.093.058.738,40 USD

10.41% DER

0.61% Yield

19.26% NPM

Dr. Reddy's Laboratories Limited Stock Analysis

Dr. Reddy's Laboratories Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Dr. Reddy's Laboratories Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (21.4%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (5%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

6 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

7 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

9 Dividend Growth

The company's dividend growth has been consistently strong over the past three years, with annual increases that demonstrate its commitment to rewarding shareholders.

10 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (39.922), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

11 PBV

The stock's elevated P/BV ratio (3.66x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

Dr. Reddy's Laboratories Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Dr. Reddy's Laboratories Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Dr. Reddy's Laboratories Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Dr. Reddy's Laboratories Limited Revenue
Year Revenue Growth
2001 10.935.109.371
2002 16.604.459.562 34.14%
2003 18.017.869.226 7.84%
2004 20.124.816.574 10.47%
2005 19.471.920.384 -3.35%
2006 24.329.784.293 19.97%
2007 65.249.358.499 62.71%
2008 50.005.640.000 -30.48%
2009 69.441.000.000 27.99%
2010 70.277.000.000 1.19%
2011 74.693.000.000 5.91%
2012 96.737.000.000 22.79%
2013 116.266.000.000 16.8%
2014 132.170.000.000 12.03%
2015 148.189.000.000 10.81%
2016 154.708.000.000 4.21%
2017 140.809.000.000 -9.87%
2018 142.028.000.000 0.86%
2019 153.851.000.000 7.68%
2020 174.600.000.000 11.88%
2021 189.722.000.000 7.97%
2022 214.391.000.000 11.51%
2023 245.879.000.000 12.81%
2024 275.208.000.000 10.66%
2024 279.164.000.000 1.42%
2025 306.908.000.000 9.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Dr. Reddy's Laboratories Limited Research and Development Expenses
Year Research and Development Expenses Growth
2001 506.990.968
2002 740.845.460 31.57%
2003 1.370.948.013 45.96%
2004 1.995.965.387 31.31%
2005 2.803.318.631 28.8%
2006 2.158.497.535 -29.87%
2007 2.468.483.875 12.56%
2008 3.532.880.000 30.13%
2009 4.037.000.000 12.49%
2010 3.793.000.000 -6.43%
2011 5.060.000.000 25.04%
2012 5.911.000.000 14.4%
2013 7.673.000.000 22.96%
2014 12.402.000.000 38.13%
2015 17.449.000.000 28.92%
2016 17.834.000.000 2.16%
2017 19.551.000.000 8.78%
2018 18.265.000.000 -7.04%
2019 15.607.000.000 -17.03%
2020 15.410.000.000 -1.28%
2021 16.541.000.000 6.84%
2022 17.482.000.000 5.38%
2023 19.381.000.000 9.8%
2024 21.788.000.000 11.05%
2024 22.873.000.000 4.74%
2025 24.772.000.000 7.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Dr. Reddy's Laboratories Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 46.466.000.000 100%
2024 0 0%
2024 0 0%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Dr. Reddy's Laboratories Limited EBITDA
Year EBITDA Growth
2001 2.315.471.381
2002 5.637.520.148 58.93%
2003 4.076.019.393 -38.31%
2004 2.834.967.596 -43.78%
2005 826.244.498 -243.11%
2006 2.707.245.438 69.48%
2007 15.444.376.230 82.47%
2008 8.394.400.000 -83.98%
2009 15.509.000.000 45.87%
2010 15.188.000.000 -2.11%
2011 12.625.000.000 -20.3%
2012 20.331.000.000 37.9%
2013 22.489.000.000 9.6%
2014 26.032.000.000 13.61%
2015 26.286.000.000 0.97%
2016 29.619.000.000 11.25%
2017 13.498.000.000 -119.43%
2018 11.917.000.000 -13.27%
2019 23.606.000.000 49.52%
2020 49.527.000.000 52.34%
2021 48.858.000.000 -1.37%
2022 52.642.000.000 7.19%
2023 108.784.000.000 51.61%
2024 88.140.000.000 -23.42%
2024 82.574.000.000 -6.74%
2025 86.844.000.000 4.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Dr. Reddy's Laboratories Limited Gross Profit
Year Gross Profit Growth
2001 5.220.018.871
2002 9.743.014.376 46.42%
2003 10.201.470.286 4.49%
2004 10.758.438.689 5.18%
2005 10.086.113.012 -6.67%
2006 11.880.269.554 15.1%
2007 30.948.717.032 61.61%
2008 25.408.040.000 -21.81%
2009 36.500.000.000 30.39%
2010 36.340.000.000 -0.44%
2011 40.263.000.000 9.74%
2012 53.305.000.000 24.47%
2013 60.579.000.000 12.01%
2014 75.801.000.000 20.08%
2015 85.403.000.000 11.24%
2016 92.281.000.000 7.45%
2017 78.356.000.000 -17.77%
2018 76.304.000.000 -2.69%
2019 83.430.000.000 8.54%
2020 94.009.000.000 11.25%
2021 103.077.000.000 8.8%
2022 113.840.000.000 9.45%
2023 202.972.000.000 43.91%
2024 161.472.000.000 -25.7%
2024 163.607.000.000 1.3%
2025 185.376.000.000 11.74%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Dr. Reddy's Laboratories Limited Net Profit
Year Net Profit Growth
2001 739.278.409
2002 4.915.629.495 84.96%
2003 3.522.180.471 -39.56%
2004 2.479.522.894 -42.05%
2005 211.266.364 -1073.65%
2006 1.633.054.152 87.06%
2007 9.348.943.096 82.53%
2008 4.678.040.000 -99.85%
2009 -5.168.000.000 190.52%
2010 1.068.000.000 583.9%
2011 11.040.000.000 90.33%
2012 14.262.000.000 22.59%
2013 16.777.000.000 14.99%
2014 21.512.000.000 22.01%
2015 22.179.000.000 3.01%
2016 20.013.000.000 -10.82%
2017 12.039.000.000 -66.23%
2018 9.806.000.000 -22.77%
2019 18.795.000.000 47.83%
2020 19.498.000.000 3.61%
2021 17.238.000.000 -13.11%
2022 23.568.000.000 26.86%
2023 45.067.000.000 47.7%
2024 59.200.000.000 23.87%
2024 55.684.000.000 -6.31%
2025 55.680.000.000 -0.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Dr. Reddy's Laboratories Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 6
2002 32 84.38%
2003 23 -39.13%
2004 16 -53.33%
2005 1 -1400%
2006 11 90%
2007 58 82.76%
2008 23 -163.64%
2009 -31 173.33%
2010 6 600%
2011 65 90.77%
2012 84 22.62%
2013 99 14.29%
2014 127 22.22%
2015 130 3.08%
2016 117 -11.11%
2017 72 -62.5%
2018 59 -22.03%
2019 113 47.79%
2020 118 3.42%
2021 104 -13.59%
2022 142 27.46%
2023 271 47.6%
2024 356 23.66%
2024 335 -5.97%
2025 334 -0.3%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Dr. Reddy's Laboratories Limited Free Cashflow
Year Free Cashflow Growth
2001 127.667.300
2002 3.558.533.539 96.41%
2003 2.842.796.512 -25.18%
2004 1.587.028.274 -79.13%
2005 542.445.386 -192.57%
2006 -272.346.503 299.17%
2007 7.084.891.746 103.84%
2008 -646.960.000 1195.11%
2009 -256.000.000 -152.72%
2010 8.943.000.000 102.86%
2011 -3.597.000.000 348.62%
2012 7.565.000.000 147.55%
2013 5.981.000.000 -26.48%
2014 8.836.000.000 32.31%
2015 9.706.000.000 8.96%
2016 26.372.000.000 63.2%
2017 -19.471.000.000 235.44%
2018 6.986.000.000 378.71%
2019 21.213.000.000 67.07%
2020 23.726.000.000 10.59%
2021 23.142.000.000 -2.52%
2022 9.059.000.000 -155.46%
2023 40.009.000.000 77.36%
2024 17.998.000.000 -122.3%
2024 13.987.000.000 -28.68%
2025 2.072.000.000 -575.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Dr. Reddy's Laboratories Limited Operating Cashflow
Year Operating Cashflow Growth
2001 614.870.303
2002 4.647.679.667 86.77%
2003 4.354.171.082 -6.74%
2004 4.007.896.068 -8.64%
2005 2.291.615.601 -74.89%
2006 1.647.402.250 -39.1%
2007 11.832.504.518 86.08%
2008 6.122.640.000 -93.26%
2009 4.505.000.000 -35.91%
2010 13.226.000.000 65.94%
2011 8.009.000.000 -65.14%
2012 16.150.000.000 50.41%
2013 13.317.000.000 -21.27%
2014 19.463.000.000 31.58%
2015 25.033.000.000 22.25%
2016 41.247.000.000 39.31%
2017 21.513.000.000 -91.73%
2018 18.029.000.000 -19.32%
2019 28.704.000.000 37.19%
2020 29.841.000.000 3.81%
2021 35.703.000.000 16.42%
2022 28.108.000.000 -27.02%
2023 58.873.000.000 52.26%
2024 45.433.000.000 -29.58%
2024 17.926.000.000 -153.45%
2025 8.496.000.000 -110.99%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Dr. Reddy's Laboratories Limited Capital Expenditure
Year Capital Expenditure Growth
2001 487.203.003
2002 1.089.146.128 55.27%
2003 1.511.374.569 27.94%
2004 2.420.867.794 37.57%
2005 1.749.170.215 -38.4%
2006 1.919.748.753 8.89%
2007 4.747.612.771 59.56%
2008 6.769.600.000 29.87%
2009 4.761.000.000 -42.19%
2010 4.283.000.000 -11.16%
2011 11.606.000.000 63.1%
2012 8.585.000.000 -35.19%
2013 7.336.000.000 -17.03%
2014 10.627.000.000 30.97%
2015 15.327.000.000 30.66%
2016 14.875.000.000 -3.04%
2017 40.984.000.000 63.71%
2018 11.043.000.000 -271.13%
2019 7.491.000.000 -47.42%
2020 6.115.000.000 -22.5%
2021 12.561.000.000 51.32%
2022 19.049.000.000 34.06%
2023 18.864.000.000 -0.98%
2024 27.435.000.000 31.24%
2024 3.939.000.000 -596.5%
2025 6.424.000.000 38.68%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Dr. Reddy's Laboratories Limited Equity
Year Equity Growth
2001 5.237.432.280
2002 15.440.468.747 66.08%
2003 18.777.727.127 17.77%
2004 21.084.990.155 10.94%
2005 20.953.143.015 -0.63%
2006 22.329.294.071 6.16%
2007 41.687.256.960 46.44%
2008 47.066.600.000 11.43%
2009 42.045.000.000 -11.94%
2010 42.915.000.000 2.03%
2011 45.990.000.000 6.69%
2012 57.444.000.000 19.94%
2013 731.045.000.000 92.14%
2014 90.801.000.000 -705.11%
2015 111.302.000.000 18.42%
2016 128.336.000.000 13.27%
2017 124.044.000.000 -3.46%
2018 126.460.000.000 1.91%
2019 140.197.000.000 9.8%
2020 154.988.000.000 9.54%
2021 174.981.000.000 11.43%
2022 190.527.000.000 8.16%
2023 232.861.000.000 18.18%
2024 280.550.000.000 17%
2024 253.086.000.000 -10.85%
2025 294.627.000.000 14.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Dr. Reddy's Laboratories Limited Assets
Year Assets Growth
2001 11.839.908.296
2002 18.946.182.209 37.51%
2003 23.025.310.520 17.72%
2004 26.677.051.158 13.69%
2005 29.288.339.088 8.92%
2006 68.945.818.295 57.52%
2007 86.122.731.653 19.94%
2008 85.445.040.000 -0.79%
2009 83.792.000.000 -1.97%
2010 80.330.000.000 -4.31%
2011 95.005.000.000 15.45%
2012 119.477.000.000 20.48%
2013 1.423.690.000.000 91.61%
2014 170.223.000.000 -736.37%
2015 194.762.000.000 12.6%
2016 207.650.000.000 6.21%
2017 219.821.000.000 5.54%
2018 225.604.000.000 2.56%
2019 225.427.000.000 -0.08%
2020 232.241.000.000 2.93%
2021 265.491.000.000 12.52%
2022 296.654.000.000 10.5%
2023 322.851.000.000 8.11%
2024 387.518.000.000 16.69%
2024 347.022.000.000 -11.67%
2025 415.297.000.000 16.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Dr. Reddy's Laboratories Limited Liabilities
Year Liabilities Growth
2001 6.602.476.015
2002 3.505.713.461 -88.33%
2003 4.247.583.392 17.47%
2004 5.592.061.003 24.04%
2005 8.335.196.073 32.91%
2006 46.616.524.224 82.12%
2007 44.435.474.692 -4.91%
2008 38.378.440.000 -15.78%
2009 41.747.000.000 8.07%
2010 37.415.000.000 -11.58%
2011 49.015.000.000 23.67%
2012 62.033.000.000 20.99%
2013 692.645.000.000 91.04%
2014 79.422.000.000 -772.11%
2015 83.460.000.000 4.84%
2016 79.314.000.000 -5.23%
2017 95.777.000.000 17.19%
2018 99.144.000.000 3.4%
2019 85.230.000.000 -16.33%
2020 77.253.000.000 -10.33%
2021 90.510.000.000 14.65%
2022 106.127.000.000 14.72%
2023 89.990.000.000 -17.93%
2024 106.968.000.000 15.87%
2024 93.936.000.000 -13.87%
2025 120.670.000.000 22.15%

Dr. Reddy's Laboratories Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1729.8
Net Income per Share
333.23
Price to Earning Ratio
19.84x
Price To Sales Ratio
3.82x
POCF Ratio
25.83
PFCF Ratio
52.46
Price to Book Ratio
3.74
EV to Sales
3.91
EV Over EBITDA
13.49
EV to Operating CashFlow
26.4
EV to FreeCashFlow
53.68
Earnings Yield
0.05
FreeCashFlow Yield
0.02
Market Cap
1.101,09 Bil.
Enterprise Value
1.126,86 Bil.
Graham Number
3639.34
Graham NetNet
414.04

Income Statement Metrics

Net Income per Share
333.23
Income Quality
0.77
ROE
0.2
Return On Assets
0.13
Return On Capital Employed
0.22
Net Income per EBT
0.77
EBT Per Ebit
1.06
Ebit per Revenue
0.24
Effective Tax Rate
0.23

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.59
Operating Profit Margin
0.24
Pretax Profit Margin
0.25
Net Profit Margin
0.19

Dividends

Dividend Yield
0.01
Dividend Yield %
0.61
Payout Ratio
0.12
Dividend Per Share
0.48

Operating Metrics

Operating Cashflow per Share
255.89
Free CashFlow per Share
125.86
Capex to Operating CashFlow
0.51
Capex to Revenue
0.08
Capex to Depreciation
1.44
Return on Invested Capital
0.16
Return on Tangible Assets
0.15
Days Sales Outstanding
102.59
Days Payables Outstanding
105.41
Days of Inventory on Hand
211.9
Receivables Turnover
3.56
Payables Turnover
3.46
Inventory Turnover
1.72
Capex per Share
130.03

Balance Sheet

Cash per Share
567,35
Book Value per Share
1.766,49
Tangible Book Value per Share
1518.43
Shareholders Equity per Share
1766.49
Interest Debt per Share
191.95
Debt to Equity
0.1
Debt to Assets
0.07
Net Debt to EBITDA
0.31
Current Ratio
2.55
Tangible Asset Value
253,25 Bil.
Net Current Asset Value
148,52 Bil.
Invested Capital
285232000000
Working Capital
163,52 Bil.
Intangibles to Total Assets
0.1
Average Receivables
88,21 Bil.
Average Payables
27,83 Bil.
Average Inventory
66060000000
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Dr. Reddy's Laboratories Limited Dividends
Year Dividends Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 1 0%
2024 0 0%

Dr. Reddy's Laboratories Limited Profile

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

CEO
Mr. Erez Israeli M.B.A.
Employee
27.048
Address
8-2-337, Road No. 3
Hyderabad, 500034

Dr. Reddy's Laboratories Limited Executives & BODs

Dr. Reddy's Laboratories Limited Executives & BODs
# Name Age
1 Ms. Archana Bhaskar B.Sc., M.B.A.
EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
70
2 Mr. Patrick Aghanian B.A., M.B.A.
Chief Executive Officer of European Generics & Member of Management Council
70
3 Mr. Deepak Sapra M.B.A.
Chief Executive Officer of API & Services & Member of Management Council
70
4 Mr. Mannam Venkatanarasimham
Chief Financial Officer & Member of the Management Council
70
5 Mr. Kallam Satish Reddy B.Tech., M.S.
Chairman of the Board & Member of the Management Council
70
6 Mr. Krishna K. Venkatesh B.Pharma M.S.
Global Head of Quality and Pharmacovigilance & Member of the Management Council
70
7 Mr. Venkata Ramana Motupalli M.B.A.
Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council
70
8 Mr. Sanjay Sharma B.Tech.
Executive Vice President, Global Head of Global Manufacturing & Member of Management Council
70
9 Mr. Gunupati Venkateswara Prasad B.E.
Co-Chairman, MD & Member of Management Council
70
10 Mr. Erez Israeli M.B.A.
Chief Executive Officer & Member of the Management Council
70

Dr. Reddy's Laboratories Limited Competitors